Validation of a Spanish Version of the Leicester Cough Questionnaire in Cystic Fibrosis

Overview

Journal Chron Respir Dis

Publisher Sage Publications

Date 2021 Nov 3

PMID 34730449

Citations 2

Authors

Gerard Munoz

Javier De Gracia

Rosa Giron

Casilda Olveira

Antonio Alvarez

Maria Buxo

Surinder S Birring

Montserrat Vendrell

Affiliations

Soon will be listed here.

Abstract

Cough is a main symptom in cystic fibrosis (CF). We aim to validate a Spanish version of the Leicester Cough Questionnaire (LCQ-Sp) to measure the impact of cough in CF bronchiectasis. A prospective longitudinal multicentre study was performed. Internal consistency and score changes over a 15-day period in stable state were assessed to analyse reliability. Concurrent validity was analysed by correlation with Saint George's Respiratory Questionnaire (SGRQ) and convergent validity by assessing the association with clinical variables. Changes in scores between stable state and the first exacerbation were assessed to analyse responsiveness. 132 patients (29.73 ± 10.52 years) were enrolled in four hospitals. Internal consistency was high for the total score and good for the three domains (Cronbach's α 0.81-0.93). The test-retest reliability showed an intraclass correlation coefficient of 0.86 for the total score. The correlation between LCQ-Sp and SGRQ scores was -0.74. The LCQ-Sp score negatively correlated with sputum volume, and the mean score decreased at the beginning of exacerbations (16.04±3.81 vs 13.91±4.29) with a large effect size. The LCQ-Sp is a reliable, repeatable and responsive instrument to assess the impact of cough in CF bronchiectasis and is responsive to change in the event of exacerbations.

Citing Articles

A systematic literature review of the clinical and socioeconomic burden of bronchiectasis.

Chalmers J, Mall M, McShane P, Nielsen K, Shteinberg M, Sullivan S Eur Respir Rev. 2024; 33(173).

PMID: 39231597 PMC: 11372470. DOI: 10.1183/16000617.0049-2024.

Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia.

Zhao Q, Yang J, Sheng Y, Zhuang M, Qi M J Healthc Eng. 2022; 2022:5288148.

PMID: 35388320 PMC: 8977326. DOI: 10.1155/2022/5288148.

References

Goss C, Burns J . Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4):360-7. PMC: 2092469. DOI: 10.1136/thx.2006.060889. View

Munoz G, Buxo M, De Gracia J, Olveira C, Martinez-Garcia M, Giron R . Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Chron Respir Dis. 2016; 13(2):128-36. PMC: 5734594. DOI: 10.1177/1479972316632005. View

Moss R, Flume P, Elborn J, Cooke J, Rowe S, McColley S . Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015; 3(7):524-33. PMC: 4641035. DOI: 10.1016/S2213-2600(15)00201-5. View

Birring S, Prudon B, Carr A, Singh S, Morgan M, Pavord I . Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003; 58(4):339-43. PMC: 1746649. DOI: 10.1136/thorax.58.4.339. View

Gee L, Abbott J, Conway S, Etherington C, Webb A . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax. 2000; 55(11):946-54. PMC: 1745639. DOI: 10.1136/thorax.55.11.946. View

Murray M, Turnbull K, MacQuarrie S, Pentland J, Hill A . Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009; 34(1):125-31. DOI: 10.1183/09031936.00160508. View

Olveira G, Olveira C, Gaspar I, Cruz I, Dorado A, Perez-Ruiz E . [Validation of the Spanish version of the Revised Cystic Fibrosis Quality of Life Questionnaire in adolescents and adults (CFQR 14+ Spain)]. Arch Bronconeumol. 2010; 46(4):165-75. DOI: 10.1016/j.arbres.2010.01.006. View

Kirshner B, Guyatt G . A methodological framework for assessing health indices. J Chronic Dis. 1985; 38(1):27-36. DOI: 10.1016/0021-9681(85)90005-0. View

Henry B, Aussage P, Grosskopf C, Goehrs J . Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res. 2003; 12(1):63-76. DOI: 10.1023/a:1022037320039. View

10.

Jones P, Quirk F, Baveystock C, Littlejohns P . A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321-7. DOI: 10.1164/ajrccm/145.6.1321. View

11.

Que C, Cullinan P, Geddes D . Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax. 2005; 61(2):155-7. PMC: 2104571. DOI: 10.1136/thx.2005.043372. View

12.

Del Corral T, Percegona J, Lopez N, Valiente A, Garriga M, Seborga M . Validity of a Spanish Version of the Leicester Cough Questionnaire in Children With Cystic Fibrosis. Arch Bronconeumol. 2015; 52(2):63-9. DOI: 10.1016/j.arbres.2015.01.016. View

13.

Quittner A, Buu A, Messer M, Modi A, Watrous M . Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005; 128(4):2347-54. DOI: 10.1378/chest.128.4.2347. View

14.

Aaronson N, Alonso J, Burnam A, Lohr K, Patrick D, Perrin E . Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002; 11(3):193-205. DOI: 10.1023/a:1015291021312. View

15.

Fathi H, Moon T, Donaldson J, Jackson W, Sedman P, Morice A . Cough in adult cystic fibrosis: diagnosis and response to fundoplication. Cough. 2009; 5:1. PMC: 2634760. DOI: 10.1186/1745-9974-5-1. View

16.

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

17.

Padilla A, Olveira G, Olveira C, Dorado A, Plata A, Gaspar I . [Validity and reliability of the St George's Respiratory Questionnaire in adults with cystic fibrosis]. Arch Bronconeumol. 2007; 43(4):205-11. DOI: 10.1016/s1579-2129(07)60052-4. View

18.

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

19.

Bell S, Mall M, Gutierrez H, Macek M, Madge S, Davies J . The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019; 8(1):65-124. PMC: 8862661. DOI: 10.1016/S2213-2600(19)30337-6. View

20.

Jones P . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002; 19(3):398-404. DOI: 10.1183/09031936.02.00063702. View